STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism

This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a real-world setting. Approximately 1,300 patients will be enrolled across multiple centers in China. Patients will be followed for 90 days to assess mortality, heart function recovery, bleeding risks, and quality of life. The results will help guide personalized treatment decisions and healthcare policy.

NCT Number	NCT07603700
Lead Sponsor	Nanjing First Hospital, Nanjing Medical University
Conditions	Pulmonary Embolism, Venous Thromboembolism
Enrollment	1,300 participants
Start Date	2026-06-01
Primary Completion	2028-03-01 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-22